Cutiss Company

CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDAOrphan drug designation for the treatment of burns.
Industry: Medical Technology
Headquarters: Zurich
Founded Date: 08.03.2017
Employees Number: 11—50
Estimated Revenue: $1-10 Mn

Visit Website
https://twitter.com/hashtag/cutiss?lang=de/
Register and Claim Ownership